Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Biol 430 > Final Exam > Flashcards

Final Exam Flashcards

0
Q

Neutrophilia

1) Definition
2) Type of neutrophil disorder
3) Causes

A

1) Increased number of neutrophils usually from increased BM activity
2) Quantitative
3) Chronic Myeloid Leukemia (CML); Chronic Myeloproliferative Disorders; Leukemoid Reactions (most common cause); Inflammation; Tissue damage; Metabolic disorders; Increased stress; Exercise; pregnancy; trauma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
1
Q

Neutrophils

1) Function
2) Defects predispose patients to…
3) Types of disorders

A
  1. Phagocytic and mediate inflammation
  2. Recurrent bacterial infections
  3. Quantitative –> Number of neutrophils
    Qualitative –> Correct number of neutrophils, but not functioning correctly
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Leukemoid Reactions

1) Definition
2) Characteristics of reaction

A

1) Neutrophil response to infections (bacterial)
2) Neutrophilia; Shift to the left (may see more immature); Toxic granulation (dark/larger granules); Dohle bodies; Cytoplasmic vacuolization; increased LAP

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Qualitative disorders of neutrophils

1) Types
2) Dysfunction categories

A

1) Phagocytic/Killing defects; Chemotaxis/Motility defects; Granule function & Structure defects; Adhesion defects
2) Acquired Dysfunctions –> outside, autoimmunities; pregnancy; renal disease
Inherited Dysfunctions

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Chediak-Higashi Syndrome

1) Type of neutrophil disorder
2) Characteristics

A

1) Inherited qualitative neutrophil disorder –> Defect of cytoplasmic granules
2) Release of enzymes inhibited by formation of giant lysosomal granules, defective chemotaxis and degranulation; Partially albino; Dohle bodies; vacuoles; fused/large granules

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Chronic Granulomatous Disease

1) Definition
2) Type of neutrophil disorder

A

1) Failure to make superoxide

2) Qualitative, inherited disorder –> Biochemical disturbance of respiratory burst (defect in respiratory enzymes)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Lazy Leukocyte Syndrome

1) Type of disorder

A

1) Qualitative, inherited neutrophil disorder –> chemotaxis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Hypersegmentation

1) Cause

A

1) Megaloblastic anemia (B12 & folate deficiency), pernicious anemia, hereditary

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Hyposegmentation (“dumbbell shape”)

1) Cause

A

1) Pelger-Huet Anomaly, Acquired (drugs, leukemia, malignancies), Inherited

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Cytoplasm Changes (WBC abnormality)

A

Alder-Reilly inclusions –> larger graunles; lipid storage disease
Toxic granulation
May-Hegglin anomaly –> hereditary, larger blue cytoplasm

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Eosinophilia

A

Parasites (helminth, invasion of tissues), allergies, malignancies (leukemias), inflammation (cystic fibrosis pneumonia)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Basophilia (causes)

A

CML, allergies, inflammation, infection (chicken pox, influenza)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Monocytosis (causes)

A

Chronic infections, malignancies (lymphoma), inflammation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Absolute Lymphocyte Counts

A

Actual number of lymphocytes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Relative lymphocyte count

A

Percentage of 100 WBC differential

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Lymphocytosis

A

Increase number of lymphocytes (greater than 40%)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Lymphocytopenia

A

Decrease number of lymphocytes (less than 20%)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Types of Lymphocytes

A

Resting lymphocytes
Reactive lymphocytes
Atypical/Malignant Lymphocytes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Characteristics of resting lymphocytes

A 
Smaller size (8-12 um)
Scant, colorless to light blue cytoplasm
Round nucleus
Polyclonal 
No nucleoli 
N:C ratio- high to moderate
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Characteristics of Reactive Lymphocytes

A
  • Polyclonal
  • Larger (9-30 um)
  • Round or indented nucleus
  • Abundant and uneven stained cytoplasm with round or indented border
  • Probable nucleoli
  • Eccentric nucleus
  • Low to moderate N:C ratio
  • Azurophilic granules (pinkish granules in light blue cytoplasm)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Causes of Reactive Lymphocytes

A
  • Infectious Mononucleosis (EBV)
  • Cytomegalovirus
  • Other viruses–HIV/AIDS, rubella
  • Bacterial–chronic infections (TB)
  • Drug Reactions
  • Allergic reactions
  • Autoimmune diseases
  • Malnutrition
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Atypical/Malignant Lymphocytes

1) Characteristics
2) Causes

A

1) Similar to reactive lymphocyte; monoclonal

2) Leukemia & lymphomas

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Leukemia

1) Definition
2) Originates in..
3) Classification basis

A

1) Malignant disease of hematopoietic tissue characterized by replacement of bone marrow with abnormal blood cells
2) Bone marrow –> malignancy taking over bone marrow
3) Based on cell type in regard to cell maturity and cell lineage

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Categories of Leukemia and onsets

A
  1. Acute lymphoblastic leukemia (ALL) –> Mostly children (3/4)
  2. Acute myeloid leukemia (AML) –> Mostly adults (80%)
  3. Chronic lymphocytic leukemia (CLL) –> 40-50 yrs old
  4. Chronic myeloid leukemia (CML) –> Any age, but > 60 yrs old
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Leukemia Etiology

1) Origin

A

1) At genetic level and related to mutation or altered expression of oncogenes (turned on cancer genes) and tumor suppressor genes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

Leukemia Etiology (Causes) Factors

A

1) Hereditary –> Increases predisposition
2) Congenital chromosomal abnormalities –> Fanconi’s anemia
3) Immunodeficiency –> sex linked agammaglobinemias
4) Chronic Marrow Dysfunction –> BM shutdown, aplastic anemia
5) Environmental –> ionizing radiation, chemicals, drugs, viruses

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

Characteristics of Acute Leukemia

A

1) All ages
2) Sudden onset
3) Immature cells
4) Mild to severe anemia
5) Mild organomegaly
6) Untreated –> less than 6 months before fatal

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

Chronic Leukemia Characteristics

A

1) Adults
2) Insidious onset (few months/longer duration)
3) Mature cells
4) Mild anemia
5) Prominent organomegaly (enlarged organs)
6) Untreated –> 2-6 years until fatal

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

Acute Leukemia

1) FAB classification
2) WHO classification
3) Types
4) Signs

A

1) > 30% blasts in bone marrow aspirate smear
2) 20% blasts in BM and peripheral blood
3) Acute Myeloid Leukemia & Acute Lymphoblastic Leukemia
4) Fatigue, easy bruising, pallor, fever, infection, bleeding, weakness

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

Tests for Leukemia

A

1) Cell morphology (Auer Rods –> Diagnose AML)
2) Cytochemical Stains
* Myeloperoxidase (stains myeloid cells)
* Sudan Black B (stains for AML)
* Specific Esterase (+ for AML; neutrophil specific)
* Nonspecific Esterase (stains for monocytic cells)
* Periodic Acid-Schiff (erythroleukemias)
3) Immunological Markers (CD and TdT)
4) Cytogenetics
* Philadelphia chromosome (CML)
* Translocation T (AML)
5) Molecular Genetics

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

Treatment for Leukemia

A

1) Cytoreductive Chemotherapy –> gets rid of all cells; hope BM regenerates itself
2) Radiotherapy –> targeting certain area or can be whole body
3) Bone Marrow Transplant –> Kills off whole bone marrow; graft new donor bone marrow; takes up to three months

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q 
Acute Myeloid Leukemia
1) Onset
2-5) Characteristics 
6) Myeloperoxidase stain result
7) Sudan black stain result
8) TdT result
A
  1. Common in adults, rare in children
  2. Larger, medium-large blasts
  3. More cytoplasm than lymphoblast
  4. Auer Rods
  5. Distinct nucleoli
  6. (+) Peroxidase stain
  7. (+) Sudan Black stain
  8. TdT negative
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

Acute Lymphoblastic Leukemia

1) Onset
2) Characteristics
3) Peroxidase stain
4) Sudan black stain
5) TdT result

A

1) Common in children, rare in adults
2) Variable, small-medium blasts; scarce cytoplasm; indistinct nucleoli; no Auer Rods
3) Negative Peroxidase
4) Negative Sudan Black
5) Positive TdT

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

Acute Lymphoblastic Leukemia (FAB classification)

1) L1
2) L2
3) L3
4) Based on?

A

1) Small, uniform lymphoblasts (cookie cutter)
2) Large, pleomorphic lymphoblasts
3) Burkitt’s type; large, pleomorphic cell
4) Morphology from bone marrow aspirate

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
34
Q

Acute Lymphoblastic Leukemia (WHO classification)

1) Based upon?

A

Lymphocyte stage of development using cytogenetics and immunophenotyping and molecular testing

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
35
Q

Chronic Myeloproliferative Disorders

1. Definition

A
  1. Malignant transformation and clonal expansion of a hematopoietic pluripotent cell line –> putting out cells that are non functional
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
36
Q

Chronic Myeloproliferative Disorders

  1. Characteristics
  2. Age of onset
A
  1. Hypercellular bone marrow (hyperplasia)
    Increase in one or more cell lines
    Splenomegaly
    Extramedullary hematopoiesis
    Increase platelets
    Hemorrhagic and thrombotic complications
    Fibroblastic proliferation in bone marrow
    Cytogenetics and molecular abnormalities
  2. Usually 50 years or older
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
37
Q

Chronic Myeloproliferative Disorder

1. Types of diseases

A
  1. Chronic Myelogenous Leukemia
  2. Polycythemia vera
  3. Essential Thrombocytopenia
  4. Chronic Idiopathic Myeloproliferative
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
38
Q

Chronic Myelogenous Leukemia

  1. Definition
  2. Characteristics
  3. Onset
A
  1. Clonal myeloproliferative disorder with increased production of granulocytes and their precursors
  2. Philadelphia chromosome –> fusion of BCR/ABL protein
    Increased leukocytosis of all granulocytes
    Low to absent levels of leukocyte alkaline phosphate (LAP)
  3. 30-50 years old
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
39
Q

Chronic Myeloproliferative Leukemia

  1. Clinical course
  2. Treatment
A
  1. Chronic (2-5 years –> if controlled by chemotherapy); Accelerated (1/2-1 1/2 years –> more blasts, shift to the left); Blastic acute (3-4 months –> nonresponsive to treatment)
  2. gamma INF therapy; chemotherapy; bone marrow transplant
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
40
Q

Chronic Idiopathic Myelofibrosis

  1. Type of disorder
  2. Characteristics
  3. Treatment
A
  1. Chronic Myeloproliferative Disorder
  2. Mutation of single multipotential stem cell with bone marrow fibrosis (dry tap); chromosome abnormalities; cytokines; extramedullary hematopoiesis; splenomegaly; teardrop; poiklocytosis in peripheral blod with immature granulocytes and nucleated red blood cells; anemia (normochromic/normocytic); dysfunctional platelets; bone marrow fibrosis
  3. Chemotherapy or bone marrow transplant
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
41
Q

Erythrocytosis

  1. Definition
  2. Absolute
  3. Relative
  4. Types
A
  1. Abnormal increase in number of RBCs in circulation (high hematocrit or hemoglobin levels)
  2. Increased RBC mass with increase RBC
  3. Normal RBC mass with decrease plasma volume (less liquid volume –> dehydration or stress)
  4. Polycythemia vera, Secondary Erythrocytosis; Relative Erythrocytosis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
42
Q

Polycythemia Vera

1. Definition

A

Accelerated erythropoisis with varying degree of myeloid and megakaryocytic elements in hypercellular bone marrow

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
43
Q

Polycythemia Vera

  1. Physical Signs
  2. Treatment
A
  1. Red complexion; dizzy; verigo; thrombotic episodes (sluggish blood)
  2. Myelosuppressive therapy –> suppress activity of the bone marrow
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
44
Q

Polycythemia Vera Characteristics

A

Increased RBC mass, RBC count, Hct, Hgb, LAP score & serum B12

Decreased erythropoietin (key feature)
Splenomegaly 
Leukocytosis
Thrombocytosis
Normal arterial oxygen saturation
Hyper-viscosity
Gradual onset
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
45
Q

Secondary Erythrocytosis

1. Definition

A

Increased erythropoietin secretion in response to:

  1. Tissue hypoxia (lack of oxygen to the tissues)
  2. Inappropriate or pathological secretion with no tissue hypoxia (renal disease/tumors)
  3. Defective oxygen transport (smokers, increase pollution)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
46
Q

Secondary Erythrocytosis

1. Characteristics

A
  1. Increased Hct; normal LAP, B12, WBC and platelet numbers; decreased arterial oxygen saturation; no splenomegaly
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
47
Q

Relative Erythrocytosis

1. Defintion & Characteristics

A

Increase hematocrit with normal RBC mass and decreased plasma volume
Normal erythropoietin; normal arterial oxygen saturation; normal LAP, B12, WBC and platelet counts; no splenomegaly

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
48
Q

Relative Erythrocytosis

1. Cause

A

Dehydration -> burn patients

Stress erythrocytosis -> obese, smokers, hypertensive, physical stress, extreme alcohol consumption, diuretic therapy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
49
Q

Essential Thrombocythemia

1. Characteristics

A
  • Marked thrombocytosis and abnormal platelet function
  • Hypercellular bone marrow with increased megakaryocytes
  • No Ph chromosome –> rules out CML
  • Absent marrow fibrosis
  • Stainable iron in bone marrow –> rules out iron def. anemia
  • Hemorrhage
  • Thrombosis
  • Splenomegaly
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
50
Q

Essential Thrombocythemia

1. Treatment

A

Platelet phoresis
Aspirin
Cytokine therapy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
51
Q

In order to diagnose Essential Thrombocythemia, what must be ruled out?

A
  1. Chronic infection
  2. Trauma
  3. Drugs
  4. Reactive thrombocytosis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
52
Q

Myelodysplastic Syndrome

  1. Definition
  2. Characteristics
  3. Treatment
  4. Onset
A
  1. Clonal hematological malignancies, cytopenias, dysplastic blood cells, and tendency to transform into acute leukemia
  2. Abnormalities in all cell lines (peripheral blood); anemia not responsive to therapy –> Refractory Anemia; Ringed Sideroblasts in bone marrow
  3. Bone marrow transplant
  4. 70-80 years old
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
53
Q

Lymphomas

  1. Definition
  2. Types
A
  1. Group of diseases that arise from cells of lymphoid tissue (lymphocytes, histiocytes, reticulum cells)
  2. Hodgkin’s Lymphoma & Non-Hodgkin’s Lymphoma
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
54
Q

Staging of Lymphoma

1. Clinical Staging

A

–> Patient history, physical exam, chemical panel, CBC, chest x-ray

A. Asymptomatic –> no signs or symptoms
B. Symptoms –> unexplained weight loss, night sweats, low grade fever

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
55
Q

Staging of Lymphoma

1. Pathological Staging

A
  1. Tissue biopsy –> Lymph nodes –> what tissue and cell type
    A. Microscopic evaluation
    B. Histological evaluation
  2. Ancillary Tests –> what stage cell is in
    A. Immunphenotyping
    B. Cytogenetics
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
56
Q

Hodgkin’s Lymphoma (1/3)

  1. Onset (ages and type of distribution)
  2. Characteristics
A
  1. Biomodal distribution –> 15-35 yrs old and >50 yrs old
  2. **Reed-Sternberg Cell
    * Tissue Biopsy –> Classification based on growth pattern and cellular composition
    * Clinical and pathological staging
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
57
Q

What characteristics classify a Hodgkin’s Lymphoma?

A

Tissue location and cell types involved

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
58
Q

Non-Hodgkin’s Lymphoma

  1. Etiology
  2. How to classify
  3. Characteristic
A
  1. Genetic damage associated with numerical or structural damage to chromosomes that would regulate growth and reproduction of cells in the immune system
  2. Classify according to clinical, morphological, immunophenotype, genotype
  3. Each lymphoid compartment occupied by distinct set of cells
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
59
Q

Diagnostic Evaluation

A
  1. Benign versus Malignant
  2. Lymphoma versus Nonlymphoma
  3. T cell versus B cell Lymphoma
  4. Hodgkin’s versus Non-Hodgkin’s
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
60
Q

Treatment of Non-Hodgkin’s Lymphoma

A
  1. Indolent –> mantle/marginal, low grade lymphoma, clinically slower progressing, incurable
  2. Diffuse aggressive –> with no treatment die within 1 year, higher cure rate with aggressive treatment, more favorable
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
61
Q

Chronic Leukemia

1) Definition
2) Types

A
  1. Clonal proliferation of morphologically and immunophenotypically mature T and B cells –> slow progressing disease
  2. Leukemia -> affects bone marrow and manifests in peripheral blood
    Lymphoma -> affects lymph nodes (sometimes bone marrow or extramedullary sites) –> tied with leukemia (can turn into)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
62
Q

Chronic Lymphocytic Leukemia/Chronic Lymphocytic Lymphoma (CLL)

  1. Onset
  2. Definition
  3. Characteristics of blood cells
A
  1. Patient usually >50 years old
  2. Lymphoproliferative disorder of mature lymphocytes (B-CLL or T-CLL)
  3. Lymphocytosis; “Soccer Ball” appearing nuclear chromatin; Smudge cells; Hypogammaglobinemia (low antibodies)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
63
Q

Classic CLL

  1. Definition
  2. Characteristics
  3. Immunophenotype
A
  1. Neoplastic disorder with gradual accumulation of small mature B cells which are long lived, nonproliferating, and dysfunctional
  2. Malignant B cells do not mature to plasma cells; abnormal chromosome
  3. slg, CD19, CD20, CD5, CD23, CD43
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
64
Q

Signs of CLL

A 
Chronic fatigue
Organomegaly 
Infections
Two times more common in males
Increased lymphocytosis in bone marrow
Thrombocytopenia 
Decrease WBC antibody count
Monoclonal cells (cookie cutter)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
65
Q

Treatment options for CLL

A
  • Chemotherapy and radiation
  • splenectomy
  • Increase dose gamma globulin therapy
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
66
Q

Multiple Myeloma

  1. Definition
  2. General characteristic
  3. Causes
A
  1. Overproduction of abnormal plasma cells
  2. Mutated plasmablast relocates to bone marrow and produces clone (plasmacytoma)
  3. Expanding plasma cell mass; overproduction of monoclonal immunoglobulins; production of osteoclast-activating factor and cytokines
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
67
Q

Signs and symptoms of Multiple Myeloma

A
  • Hypercalcemia
  • Kidney stones
  • Mental status change
  • Constipation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
68
Q

Plasmacytoma

A

Single tumor mass of plasma cells –> relocates to the bone marrow

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
69
Q

Multiple Myeloma –> Expanding Plasma Cell Mass

  1. Definition
  2. Characterized by..
A
  1. Normal bone marrow replaced by steadily growing clone of plasma cell
  2. Pancytopenia with anemia, increased bleeding (decreased platelets) and increased infections (decreased WBC), bone pain (due to masses in heme rich areas of vertebrae)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
70
Q

Multiple Myeloma –> Overproduction of Monoclonal Immunoglobulins (Monoclonal Gammopathy)

  1. Definition
  2. Characteristics
A
  1. Unbalanced production of free light or free heavy chains
  2. *Hyperviscosity syndrome (increase in viscosity = thick blood = increased heart workload)
    * Decreased production of normal Igs
    * Bence-Jones Protein (increase in light chains) /Kidney damage
    * Amyloidosis (accumulation of light chains in body organs)
    * Bleeding disorders and cryoglobulins (increase AB components and increase in IgGs)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
71
Q

Multiple Myeloma –> Production of Osteoclast-Activating Factor and Cytokines

A
  1. OAF increases bone resorption and calcium release (lytic or “punched out” lesions)
  2. IL-6 (increases apoptosis & plasma cell growth)
  3. Hypercalcemia
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
72
Q

Multiple Myeloma

1. Signs and Symptoms

A
  • Psychosis
  • Confusion
  • Bone pain
  • Kidney stones
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
73
Q

Multiple Myeloma

1. Lab results

A
  • M-spike on protein electrophoresis
  • Normocytic anemia
  • Rouleaux
  • Increased ESR, CRP, and Calcium
  • Bone Marrow biopsy
  • Radiology, CT, and MRI
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
74
Q

Lipid Storage Diseases

  1. Definition
  2. Characterized by…
  3. Types
A
  1. Rare, autosomally inherited diseases
  2. Subcellular accumulation of unmetabolized material in lysosomes of various cells
    * Enzyme defect and/or deficiency affecting lipid metabolism
  3. Gaucher’s, Niemann-Pick, Tay-Sachs, Mucopolysaccharidosis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
75
Q

Gaucher’s Disease

  1. Deficiency of…
  2. Result of this deficiency
  3. Characteristics
A
  1. Beta-glucocerebrosidase
  2. Accumulation of unmetabolized glucocerebroside in cells of the RE system
  3. Gaucher’s cells (histiocytes) –> crumpled paper cytoplasm
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
76
Q

Niemann-Pick Disease

  1. Deficiency of..
  2. Result of deficiency
  3. Characteristics
A
  1. Sphingomyelinase
  2. Secondary accumulation of unmetabolized lipid sphingomyelin and cholesterol
  3. Niemann-Pick cells (foamy, bubbled milk cytoplasm)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
77
Q

Tay-Sachs Disease

  1. Deficiency of…
  2. Results in…
  3. Characteristics
A
  1. Hexosaminidase A (increase in hexosaminidase B)
  2. Accumulation of unmetabolized GM2 ganglioside in tissues
  3. Macrocephaly, cherry-red spot in eye, death by 4 years of age
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
78
Q

Mucopolysaccharidoses

  1. Definition
  2. How many different categories?
  3. Characterized by..
A
  1. Group of disorders deficient in one of the enzymes in the breakdown of mucopolysaccharides
  2. MPS I-VII (7)
  3. Alder-Reilly Bodies
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
79
Q

Hemostasis

1. Definition

A

Maintain complete balance between clotting and bleeding

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
80
Q

What are the major systems that regulate hemostasis?

A
  • Vascular system
  • Platelets
  • Serine Protease Inhibitors
  • Coagulation system
  • Fibrinolytic system
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
81
Q

What are the minor systems maintaining hemostasis?

A
  • Kinin system

* Complement system

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
82
Q

Stages of Hemostasis

A
  • Primary Hemostasis

* Secondary Hemostasis

83
Q

Primary Hemostasis

  1. Initiation
  2. Characterized by..
A
  1. Initiated when blood vessel is exposed

2. Platelet adhesion to exposed collagen within endothelium of vessel wall and mediated by GPIb and vWF

84
Q

GPIb

A

Found on platelets and is a receptor for vWF

85
Q

vWF

A

Secreted by endothelial and megakaryocytes

Found on blood vessel walls

86
Q

Secondary Hemostasis

  1. Function
  2. Characterized by..
A
  1. Stabilization of platelet plug
  2. Activation of coagulation proteins to produce fibrin from fibrinogen to stabilize clot
    * Fibrinolysis (plasmin) and PDGF
87
Q

Sources and Types of Bleeding

  1. Arteriole, venule
  2. Veins
  3. Artery
A
  1. Pinpoint petechial, hemorrhage
  2. Ecchymosis –> soft tissue bleeding, blood leaking from vein
  3. Rapidly expanding blowout hemorrhage
88
Q

Vessel layers and characteristics of each layer

A
  1. Tunica adventitia (outermost layer) –> connective tissue support
  2. Tunica media (middle layer) –> controls vasodilation and constriction, smooth muscle
  3. Tunica intima (inner layer) –> nonwettable surface (nonthrombogenic)
89
Q

Vascular System’s role in prevention of bleeding

A
  1. Vasoconstriction
  2. Diversion of blood flow
  3. Contact activation of platelets
  4. Activation of coagulation system (secondary hemostasis) leading to fibrin formation
90
Q

Primary Hemostasis –> Platelets

  1. Definition
  2. Secreted by?
  3. Physical characteristics?
A
  1. Anucleated cytoplasmic fragments
  2. From bone marrow megakaryocytes
  3. 2-4 um and 150,000-400,000/uL –> reserved in the spleen
91
Q

Functions of platelets in primary hemostasis

A
  1. Provide (-) charged phospholipid surface for Factor X and prothrombin activation and binding
  2. Release substances for vasoconstriction, platelet aggregation, coagulation, and repair
  3. Provide surface membrane glycoproteins to attach to other platelets, endothelium
92
Q

Platelet Structure –> what are the main areas?

A
  1. Peripheral Zone
  2. Sol-Gel Zone
  3. Organelle Zone
93
Q

Platelet structure –> Peripheral Zone (outer zone)

  1. Glycocalyx
  2. Platelet membrane
  3. Open Canalicular system
  4. Submembrane region
A
  1. Responsible for antigens on surface (ABO/MHC)
  2. Shape changes/stickiness/signal transduction
  3. Moves granules
  4. Microfilaments for support
94
Q

Platelet structure –> Sol-Gel Zone (support system - cytoskeleton)

  1. Microtubules
  2. Microfilaments
A
  1. Encase the whole platelet –> maintain shape

2. Randomly distributed –> anticipate contraction

95
Q

Platelet Structure –> Organelle Zone

  1. Granules (types)
  2. Mitochondria
  3. Dense Tubular System
  4. Peroxisomes
A
  1. Dense Granules (store ADP, ATP, calcium, serotonin), Alpha Granules (200/platelet), Lysosomes (neutralizing proteases), Glycogen Granules (help function in metabolism)
  2. Use glycogen to get ATP
  3. Sequester calcium – site for thromboxane production
  4. Nothing to know about this
96
Q

Platelet Plug Formation Pathway (General steps)

A
  1. Vasoconstriction
  2. Adhesion
  3. Platelet Activation – Shape Change
  4. Aggregation
  5. Secretion (release reaction)
  6. Stabilization of Platelet Plug
97
Q

Platelet Plug Formation

1. Vasoconstriction

A

Activated by a breach in the blood vein system

98
Q

Platelet Plug Formation

2. Adhesion (1-2 seconds)

A
  1. vWF
  2. GPIb
  3. Collagen fibers
99
Q

Platelet Plug Formation

3. Platelet Activation – Shape Change

A

Altered cytosolic calcium and microtubules

100
Q

Platelet Plug Formation

4. Aggregation (10-20 seconds)

A

Platelet to platelet interaction

  • **ATP dependent, Calcium, GPIIb and IIIa, and fibrinogen
  • *Primary or reversible (platelets can aggregate, but can dissociate if not needed at this point
101
Q

Platelet Plug Formation

5. Secretion (Release Reaction) (1-3 minutes)

A
  • *Platelets can no longer dissociate at this point
  • *Vicious metamorphosis - platelet mass – cannot distinguish individual platelets
  • *alpha granules release beta-TG, PF4, thrombospondin, PDGF
102
Q

Platelet Plug Formation
6. Stabilization of Platelet Plug
A. Function
B. Causes

A

A. Prevents blood leaking by providing structure
B Activate coagulation cascade (consolidation of plug); Formation and deposition of fibrin which interweaves with platelets; Thrombin with Factor XIII stabilizes clot

103
Q

Fibrinolysis

  1. Function
  2. Pathway
A
  1. Promotes clot dissolution (means for removing thrombi or clots)
  2. Plasminogen –> Plasmin –> breaks down fibrin and fibrinogen
104
Q

Open Canicular System

A

Control movement and release of stored granules and movement of calcium

105
Q

Microtubules/Microfilaments

A

Platelet shape and organelle movement

106
Q

Ionized Calcium

A

Shape changes (secondary hemostasis); stabilizes fibrinogen in clot

107
Q

GPIb

A

Binds vWF; encourages platelet adhesion

108
Q

PGI2

A

Vasodilator – inhibits platelet aggregation

109
Q

TXA2

A

Vasoconstrictor – platelet adherence and aggregation

110
Q

Factor XIII

A

Cross linking with fibrin and stabilizing clot

111
Q

PDGF

A

Vascular healing and repair

112
Q

Thrombin

A

Convert fibrinogen to fibrin

113
Q

Fibrinogen

A

Precursor to fibrin

114
Q

Fibrin

A

Stabilizes clot

115
Q

t-PA

A

Primary activator of plasminogen to plasmin

116
Q

Plasminogen

A

Precursor to plasmin

117
Q

Plasmin

A

Destroys fibrin and fibrinogen

118
Q

Secondary Hemostasis

1. Definition

A

Coagulation factors interact to form a fibrin clot that reinforces the platelet plug

119
Q

Factor I

A

Fibrinogen

120
Q

Factor II

A

Prothrombin

121
Q

Factor III

A

Tissue thromboplastin

122
Q

Factor IV

A

Ca++

123
Q

Factor V

A

Labile Factor

124
Q

Factor VII

A

Stable Factor

125
Q

Factor VIII

A

Antihemophilic factor or Factor VIII:C

126
Q

Factor IX

A

Christmas Factor

127
Q

Factor X

A

Stuart-Prower Factor

128
Q

Factor XI

A

Plasma thromboplastic antecedent

129
Q

Factor XII

A

Hageman Factor

130
Q

Factor XIII

A

Fibrin-stabilizing Factor

131
Q

Fitzgerald Factor

A

High-molecular weight kininogen (HMWK)

132
Q

Fletcher Factor

A

Prekallikrein (PK)

133
Q

Physical Properties Classification of Factors –> Contact

  1. Factors?
  2. Consumed in the reaction?
  3. Vitamin K dependent?
A
  1. XII, XI, Prekallikrein, HMwK
  2. Not consumed in the reaction
  3. Not vitamin K dependent
134
Q

Physical Properties Classification of Factors –> Prothrombin

  1. Factors?
  2. Consumed in the reaction?
  3. Vitamin K dependent?
A
  1. II, VII, IX, X
  2. Not consumed in the reaction except for II
  3. Vitamin K dependent
135
Q

Physical Properties Classification of Factors –> Fibrinogen Group

  1. Factors?
  2. Consumed in the reaction?
  3. Vitamin K dependent?
A
  1. I, V, VIII, XIII
  2. Consumed in reaction
  3. Not vitamin K dependent
136
Q

Coagulation Pathways

1. Types

A

Extrinsic, Intrinsic, Common

137
Q

Extrinsic Coagulation Pathway

  1. Factors
  2. Test
A
  1. III, VII –> goes into common pathway –> X, V, II, I

2. Prothrombin Times (PT)

138
Q

Intrinsic Coagulation Pathway

  1. Factors
  2. Test
A
  1. XII, XI, IX, VIII –> Goes into common –> X, V, II, I

2. Activated Partial Thromboplastin Time (APTT)

139
Q

Common Coagulation Pathway

  1. Factors
  2. Tests
A
  1. XIII, X, V, II, I

2. APTT or PT

140
Q

If platelet count and morphology are normal, how do you determine if it is a factor deficiency or factor inhibitor causing the problem?

A

Mixing studies with pooled normal plasma to determine the cause

141
Q

PT is abnormal, but is corrected with pooled normal plasma

APTT is normal

A

Deficiency of Extrinsic Factor

142
Q

PT is abnormal, but is NOT corrected with pooled normal plasma
APTT is normal

A

Inhibitors to Extrinsic Factors

143
Q

PT is normal

APTT is abnormal, but is corrected with pooled normal plasma

A

Deficiency of Intrinsic factors

144
Q

PT is normal

APTT is abnormal, but is NOT corrected with pooled normal plasma

A

Inhibitors to Intrinsic Factors

145
Q

PT and APTT is abnormal, but are corrected with pooled normal plasma

A

Deficiency of Common Factors

146
Q

PT and APTT are abnormal, but are NOT corrected with pooled normal plasma

A

Inhibitors to Common Factors

147
Q

Test Results for Vascular Disorder:

  1. PT
  2. APTT
  3. TT
  4. Platelet Count
  5. Template or Ivy Bleeding Time
  6. PFA-100 Assay (Platelet Function Assay)
A
  1. Normal
  2. Normal
  3. Normal
  4. Normal
  5. Abnormal
  6. Abnormal
148
Q

Test Results for Quantitative Platelet Disorder:

  1. PT
  2. APTT
  3. TT
  4. Platelet Count
  5. Template or Ivy Bleeding Time
  6. PFA-100 Assay (Platelet Function Assay)
A
  1. Normal
  2. Normal
  3. Normal
  4. Abnormal
  5. Abnormal
  6. Abnormal
149
Q

Test Results for Qualitative Platelet Disorder:

  1. PT
  2. APTT
  3. TT
  4. Platelet Count
  5. Template or Ivy Bleeding Time
  6. PFA-100 Assay (Platelet Function Assay)
A
  1. Normal
  2. Normal
  3. Normal
  4. Normal
  5. Abnormal
  6. Abnormal
150
Q

Test Results for Factor Deficiency Common Disorder:

  1. PT
  2. APTT
  3. TT
  4. Platelet Count
  5. Template or Ivy Bleeding Time
  6. PFA-100 Assay (Platelet Function Assay)
A
  1. Abnormal
  2. Abnormal
  3. Normal
  4. Normal
  5. Normal
  6. Normal
151
Q

Test Results for Factor Deficiency Intrinsic Disorder:

  1. PT
  2. APTT
  3. TT
  4. Platelet Count
  5. Template or Ivy Bleeding Time
  6. PFA-100 Assay (Platelet Function Assay)
A
  1. Normal
  2. Abnormal
  3. Normal
  4. Normal
  5. Normal
  6. Normal
152
Q

Test Results for Factor Deficiency Extrinsic Disorder:

  1. PT
  2. APTT
  3. TT
  4. Platelet Count
  5. Template or Ivy Bleeding Time
  6. PFA-100 Assay (Platelet Function Assay)
A
  1. Abnormal
  2. Normal
  3. Normal
  4. Normal
  5. Normal
  6. Normal
153
Q

Test Results for Factor I Deficiency:

  1. PT
  2. APTT
  3. TT
  4. Platelet Count
  5. Template or Ivy Bleeding Time
  6. PFA-100 Assay (Platelet Function Assay)
A
  1. Abnormal
  2. Abnormal
  3. Abnormal
  4. Normal
  5. Normal
  6. Normal
154
Q

Thrombin

1. Main Functions

A
  1. Converts fibrinogen to fibrin
  2. Activates XIII
  3. Enhances activity of V and VIII – enhance coagulation
  4. Induces platelet aggregation and activation
  5. Aids in tissue repair and healing (induces WBC adhesion, increases vascular permeability)
155
Q

Fibrinolytic System

  1. Definition
  2. Pathway
A
  1. Removal of fibrin deposits with enzymatic cleavage to reestablish blood flow
  2. Plasminogen with t-PA –> Plasmin –> splits fibrin into FDPs
156
Q

Fibrinolytic System

1. Plasmin function

A
  1. Destroys fibrinogen and fibrin; produce FDPs; Destroys some coagulation factors; cleaves C3; liberates kinins
157
Q

Kinin System

  1. Function
  2. Systems that activate it…
A
  1. Inflammation, permeability, vasodilation, and chemotaxis

2. Activated by coagulation and fibrinolytic systems

158
Q

Protease Inhibitors

1. Function

A
  1. Eliminate kallikrein and plasmin
159
Q

Other Systems involved in Hemostasis

A
  1. Kinin System
  2. Protease Inhibitors
  3. Complement System
160
Q

Diagnosis of Hemostatic Disorders

A
  1. Patient history
  2. Platelet count
  3. Peripheral blood smear
  4. Template Bleeding time
  5. Prothrombin time (PT)
  6. Activated Partial Thromboplastin Time (APTT)
  7. Thrombin Time (TT)
161
Q

Thrombin Time

A

Time for thrombin to convert fibrinogen to fibrin

162
Q

Disorders of Primary Hemostasis

  1. Definition
  2. Clinical symptoms
  3. Tests used to determine..
A
  1. Quantitative and qualitative platelet disorders and defects of blood vessel wall
  2. Ecchymosis, petechiae, purpura and mucosal bleeding
  3. Platelet count; Peripheral blood smear; bleeding time; vWF studies; Platelet antibody testing; platelet aggregation; Bone marrow aspirate and biopsy
163
Q

Types of Quantitative Platelet Disorders

A

Thombocytopenia and Thrombocytosis

164
Q

Thrombocytopenia

1. Causes (3)

A
  1. Deficient Platelet Production
  2. Abnormal Platelet Distribution
  3. Increased Platelet Destruction
165
Q

Thrombocytopenia –> Deficient Platelet Production

1. Causes

A
  1. Myelophthisic (bone marrow, leukemia/lymphoma)
  2. Aplasia (aplastic anemia)
  3. Ineffective Erythropoiesis (Increase alcohol consumption)
  4. Congenital disorders
166
Q

Thrombocytopenia –> Abnormal Platelet Distribution

A
  1. Hypersplenism (hyperactive spleen)

2. Hemangiomas (large tumors in blood vessels that accumulate platelets

167
Q

Thrombocytopenia –> Increased Platelet Destruction

  1. Immune (primary)
  2. Immune (secondary)
  3. Microangiopathic thrombocytopenia
  4. Pregnancy (associated)
A
  1. Idiopathic thrombocytopenic purpura; posttransfusion purpura, isoimmune neonatal; drug-induced; heparin therapy
  2. Lymphoproliferative disorders; collage vascular disorders; viral infection
  3. Thrombotic thrombocytopenia purpura; Hemolytic Uremic syndrome; Disseminated Intravascular Coagulation
  4. Gestational; Preeclampsia; Eclampsia
168
Q

Thrombocytosis

1) Types

A
  1. Primary Thrombocytosis –> Due to myeloproliferative disorders
  2. Reactive Thrombocytosis –> Acute hemorrhaging
169
Q

Qualitative Platelet Disorders

1) Types

A
  1. Platelet Membrane Defects
  2. Platelet Release (Secretion) Defects
  3. Defects in Platelet Coagulant Activity
  4. vonWillebrand’s Disease
170
Q

Qualitative Platelet Disorders –> Platelet Release (Secretion) Defects –> Causes

  1. Storage Pool Deficiencies
  2. Primary Secretion Defects
A
  1. Granule defect; Chediak-Higashi & Wiskott-Aldrich

2. Enzymatic pathway defects

171
Q

Qualitative Platelet Disorders –> vonWillebrand’s Disease –> Causes

A
  • Inherited deficiency of vWF
  • vWF promotes secondary hemostasis by functioning as carrier for Factor VIII
  • Platelet adhesion depends on vWF, GPIb, vascular endothelium (collagen), and other adhesive proteins
172
Q

Causes of acquired qualitative platelet disorders

A
  1. Renal disease
  2. Liver disease
  3. Paraproteinemias
  4. Myeloproliferative disorders
  5. Acquired vWF disease
  6. Cardiopulmonary bypass
  7. Acquired storage pool deficiencies
  8. Drug Therapy
173
Q

Vascular Disorders –> Purpora

  1. Definition
  2. Primary
  3. Secondary
A
  1. Bleeding
  2. Simple bruising, mechanical (sneezing can cause a bruise on the face, senile, factitious, Schamberg’s
  3. Result of other disease –> Infectious (strep), allergic, metabolic, psychogenic, secondary to dysproteinemia (lack of protein), vascular and connective tissue disorders
174
Q

Disorders of Plasma Clotting Factors

  1. Causes
  2. Characteristics
  3. Types
A
  1. Decrease in factor synthesis, Produce abnormal molecules that interfere with coagulation pathway; loss or consumption of factors; inactivation of factors by inhibitors or antibody
  2. Prolonged clot formation; Increased bleeding time or clot; Delayed pathway activation
  3. Inherited or acquired
175
Q

Factor I (Fibrinogen)

  1. Function
  2. Pathway
A
  1. Fibrinogen combines with thrombin to form fibrin / Acute phase reactant (inflammation reactant)
  2. Common pathway
176
Q 
Factor I (Fibrinogen) Deficiency 
1. Types
A

Afribinogenemia –> low levels of fibrinogen (increase in PT, APTT, TT)

Hypofibrinogenemia

Dysfibrinogenemia –> Dysfunction in fibrinogen (increase in PT, TT, APTT)

177
Q

Treatment options for factor deficiencies

A
  1. Fresh frozen plasma –> gives coagulation factors

2. Cryopercipitate –> high concentration of coagulation factors (esp. 8)

178
Q

Factor II (Prothrombin)

  1. Characteristics
  2. Function
  3. Pathway
A
  1. Vitamin K dependent
  2. Prothrombin with Xa, Va, Ca++, and phospholipid cofactor forms thrombin
    * Can also bind platelets and initiate platelet charge
179
Q

Factor II (Prothrombin) Deficiency

A
  • Hypoprothrombinemia –> low levels
  • Dysprothrombinemia –> dysfunctional prothrombin
  • Prothrombin mutation –> most common cause of thrombosis

**APTT, PT, TT tests

180
Q

Factor V (Proaccelerin/Labile Factor)

  1. Function
  2. Pathway
  3. Diseases/Deficiencies
A
  1. Cofactor of prothrombin –> thrombin
  2. Common Pathway (APTT, TT, PT)
  3. Parahemophilia (congenital) or Factor V mutation (affects protein C)
181
Q

Factor VII (Proconvertin/Stable Factor)

  1. Characteristic
  2. Pathway
  3. Function
  4. Deficiency types
  5. Test
A
  1. Vitamin K dependent
  2. Extrinsic Pathway
  3. VIIa and tissue factor activate factors IX and X
  4. Congenital and acquired
  5. PT test abnormal
182
Q

Factor VIII (Anti-hemophilic Factor)

  1. Pathway and test
  2. Function
  3. Disease associated
  4. Treatment of Disease
A
  1. Intrinsic pathway (APTT test)
  2. Circulates with vWF/cofactor in converting X –> Xa
  3. Hemophilia A –> sex linked defect or absence of FVIII:C/(procoagulant portion) with normal levels of vWF
  4. Cryopercipitate
183
Q

vonWillebrand’s Disease

  1. Factor associated with this disease
  2. Characterized by…
  3. Normal function of vWF
  4. Abnormal…
A
  1. Factor VIII
  2. Autosomal defect of vWF with decreased platelet adhesion; vWF in Weibel-Palade bodies in endothelial cells and alpha platelet granules
  3. Carrier for Factor VIII
  4. Abnormal bleeding time and platelet adhesion
184
Q

Factor IX (Christmas Factor)

  1. Characteristic
  2. Pathway
  3. Normal function
  4. Disease associated
A
  1. Vitamin K dependent
  2. Intrinsic pathway (APTT test)
  3. Cofactor in activating Factor X –> Xa
  4. Hemophilia B –> Sex linked inherited
185
Q

Factor X (Stuart-Prower Factor)

  1. Characteristic
  2. Pathway
  3. Function
A
  1. Vitamin K dependent
  2. Common pathway (increase in APTT and PT)
  3. Activates prothrombin to thrombin
186
Q

Factor XI (Plasma Thromboplastin Antecedent)

  1. Pathway
  2. Function
  3. Disease associated with it…
A
  1. Intrinsic pathway (APTT)
  2. Converts Factor IX –> Factor IXa
  3. Hemophilia C –> Inherited Jewish population
187
Q

Factor XII (Hageman Factor)

  1. Normal function
  2. Disease and symptoms
A
  1. Starts with intrinsic pathway as contact factor with collagen
  2. Hageman Trait –> Increase chances of thrombotic diseases; Increase thrombosis; APTT is abnormal
188
Q

Factor XIII (Fibrin-Stabilizing Factor)

  1. Special characteristic
  2. Normal function
  3. Pathway
  4. Disease characteristic
A
  1. Only one that is not a serine protease
  2. Formation of stable fibrin clot
  3. Common Pathway
  4. Normal test results, but about 36 hours after platelet plug formation person will bleed due to inability to stabilize the clot
189
Q

High-Molecular-Weight Kininogen (Fitzgerald Factor)

  1. Pathway
  2. Function
A
  1. Intrinsic pathway (APTT)

2. Contact activator cofactor with Factor XIIa and prekallikrein

190
Q

Inhibitors of Coagulation (Major types)

A
  1. Specific Factor Inhibitors

2. Nonspecific Inhibitors

191
Q

Specific Factor Inhibitors

1. Types

A
  1. Antibodies –> directly inhibit or neutralize or cause increased clearance by binding
  2. Factor VIII:C inhibitor –> Most common; alloantibody; result of transfusion
192
Q

Nonspecific Inhibitors

1. Example

A

Antiphospholipid Antibody Syndrome –> lupus anticoagulants and anticardiolipin antibody)

193
Q

Fibrinolytic System Function

A

Breaking down blood clot

194
Q

Fibrinolytic System Parts

A
  1. Plasminogen
  2. Plasminogen Activators –> t-PA
  3. Plasminogen Activator Inhibitor-1 (inhibits t-PA)
  4. Plasmin
  5. Plasmin Inhibitors
  6. Fibrinogen and Fibrin (plasmin substrates)
  7. Thrombomodulin –> Regulates thrombin – inhibits thrombin
  8. Thrombin-activatable fibrinolysis inhibitor
195
Q

Plasmin Inhibitors

  1. Function
  2. Type
A
  1. Grade reaction
  2. Alpha2-antiplasmin inhibitor –> primary, irreversible
    Alpha2-macroglobulin –> secondary
196
Q

Fibrinolytic System Abnormalities

1. Types

A
  1. Congenital and Acquired
197
Q

Acquired Fibrinolytic System Abnormality

A
  1. Disseminated Intravascular Coagulation (DIC)

2. Primary Fibrinolysis

198
Q

Disseminated Intravascular Coagulation

A

Acquired Fibrinolytic system abnormalities
–> Coagulation factors and platelets are consumed with thrombus in microcirculation; diffuse hemorrhage and/or ischemic tissue damage with vascular occlusion

199
Q

Primary Fibrinolysis

A

Acquired Fibrinolytic System Abnormality

–> Plasmin formed in absence of coagulation process

200
Q

Thrombosis

  1. Definition
  2. Causes
A
  1. Development or formation of a blood clot or thrombus

2. Stroke, myocardial infractions, pulmonary embolism

201
Q

Thrombosis

1. Factors influencing Thrombosis

A
  • Role of Blood Vessel
  • Flow of blood within the vessel
  • Chemistry of blood
  • Role of Endothelium
    • -> Prothrombotic Properties
    • -> Antithrombotic Properties
  • Platelets
  • Procoagulant Factors and generation of thrombin
202
Q

Anticoagulant Therapy

1. Types

A
  • Unfractionated Heparin
  • Low-Molecular-Weight Heparin
  • Oral Anticoagulants
  • Factor Xa Inhibitors
  • Antiplatelet Agents
  • Thrombolytic Therapy
203
Q

Unfractionated Heparin

A

Initial acute treatment for thrombosis

  • binds thrombin
  • APTT (70-100 seconds)
204
Q

Oral Anticoagulants

  1. Type of treatment
  2. Examples and function
  3. Test
A
  1. Long term treatment
  2. Coumarin (Warfarin) –> Inhibits vitamin K
  3. PT
205
Q

Antiplatelet Agents

1. Example and function

A
  1. Aspirin –> inhibits cyclo-oxygenase for TXA2 production and inhibits prostaglandin synthesis; inhibits platelet aggregation
206
Q

Thrombolytic Therapy

  1. Function
  2. Examples
A
  1. Lyse clots

2. Urokinase, Streptokinase, t-PA

Biol 430 (2 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions